HK1201039A1 - Lyophilized liposomes - Google Patents

Lyophilized liposomes

Info

Publication number
HK1201039A1
HK1201039A1 HK15100906.6A HK15100906A HK1201039A1 HK 1201039 A1 HK1201039 A1 HK 1201039A1 HK 15100906 A HK15100906 A HK 15100906A HK 1201039 A1 HK1201039 A1 HK 1201039A1
Authority
HK
Hong Kong
Prior art keywords
lyophilized liposomes
liposomes
lyophilized
Prior art date
Application number
HK15100906.6A
Other languages
English (en)
Chinese (zh)
Inventor
唐娜．卡夫拉爾-莉莉
勞倫斯．邁耶
保羅．塔爾迪
戴維．沃特金斯
曾毅
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1201039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of HK1201039A1 publication Critical patent/HK1201039A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
HK15100906.6A 2011-10-21 2015-01-27 Lyophilized liposomes HK1201039A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Publications (1)

Publication Number Publication Date
HK1201039A1 true HK1201039A1 (en) 2015-08-21

Family

ID=48141268

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100906.6A HK1201039A1 (en) 2011-10-21 2015-01-27 Lyophilized liposomes

Country Status (22)

Country Link
US (5) US10028912B2 (pt)
EP (2) EP2768484B1 (pt)
JP (6) JP6133308B2 (pt)
KR (5) KR102113753B1 (pt)
CN (2) CN104114156A (pt)
AU (1) AU2012326370C9 (pt)
BR (1) BR112014009305B1 (pt)
CA (1) CA2852777C (pt)
DK (1) DK2768484T3 (pt)
ES (1) ES2750368T3 (pt)
HK (1) HK1201039A1 (pt)
HR (1) HRP20191683T1 (pt)
HU (2) HUE045978T2 (pt)
IL (1) IL232161B (pt)
LU (1) LUC00135I2 (pt)
NL (1) NL301016I2 (pt)
NO (1) NO2019041I1 (pt)
PL (1) PL2768484T3 (pt)
PT (1) PT2768484T (pt)
RU (1) RU2648753C2 (pt)
SI (1) SI2768484T1 (pt)
WO (1) WO2013059133A1 (pt)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045978T2 (hu) * 2011-10-21 2020-01-28 Jazz Pharmaceuticals Res Llc Liofilizált liposzómák
EP3185876B1 (en) 2014-08-28 2022-08-10 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
DK3324932T3 (da) 2015-07-22 2021-04-06 Nitto Denko Corp Sammensætninger og fremgangsmåder for nanopartikel lyofile former
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
SG11201807138XA (en) 2016-02-26 2018-09-27 Massachusetts Gen Hospital Medical ice slurry production and delivery systems and methods
EP3651733A4 (en) * 2017-07-10 2021-04-07 ImmunoVaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF
KR20220027941A (ko) * 2019-06-28 2022-03-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 리포솜 아나마이신의 재구성 방법
JP2022542571A (ja) * 2019-07-24 2022-10-05 ザ ジェネラル ホスピタル コーポレイション カプセル化により異なる凝固点を有する物質を作製する方法
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493A (zh) * 2022-12-16 2023-04-25 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
WO1986003938A1 (en) 1985-01-11 1986-07-17 The Regents Of The University Of California Method for preserving liposomes
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
EP0437479B1 (en) * 1988-10-05 1994-06-22 Vestar, Inc. Method of making liposomes with improved stability during drying
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
ATE237362T1 (de) 1996-02-19 2003-05-15 Amersham Health As Thermostabilisiertes kontrastmittel
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
AU775038B2 (en) 1999-07-16 2004-07-15 Alza Corporation A liposome composition having resistance to freeze/thaw damage
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
DE60237162D1 (de) 2001-10-03 2010-09-09 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
ES2290333T3 (es) 2001-11-13 2008-02-16 Celator Pharmaceuticals, Inc. Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos.
JP4555569B2 (ja) * 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
WO2004087115A2 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination compositions of camptothecins and fluoropyrimidines
PT1744764E (pt) 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
US7893338B2 (en) * 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
CA2584279C (en) * 2004-11-05 2015-01-27 Index Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
EP1817005A1 (en) 2004-11-18 2007-08-15 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
US7842676B2 (en) 2005-10-25 2010-11-30 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR THE PREPARATION OF SAID FORMULATIONS
SI3300601T1 (sl) * 2007-02-16 2022-05-31 Rotalec Ip Holdings Llc Fiksna razmerja med zdravili za zdravljenje vrst hematopoetskega raka in proliferativnih motenj
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CN101878024B (zh) 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
EP2344161B1 (en) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
CN102271659B (zh) 2009-12-03 2013-09-18 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
EP2531175A2 (en) 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
HUE045978T2 (hu) * 2011-10-21 2020-01-28 Jazz Pharmaceuticals Res Llc Liofilizált liposzómák

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en) 2016-07-22 2024-10-08 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115143B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115145B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115144B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115142B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
KR102284689B1 (ko) 2021-08-02
US20210169803A1 (en) 2021-06-10
CA2852777C (en) 2020-10-27
SI2768484T1 (sl) 2019-12-31
KR20210095746A (ko) 2021-08-02
AU2012326370C1 (en) 2023-03-30
HUS1900047I1 (hu) 2019-11-28
US20140255475A1 (en) 2014-09-11
CN104114156A (zh) 2014-10-22
EP3572071A1 (en) 2019-11-27
IL232161B (en) 2019-07-31
EP2768484A1 (en) 2014-08-27
KR20140092323A (ko) 2014-07-23
RU2014120475A (ru) 2015-11-27
JP2018150342A (ja) 2018-09-27
HUE045978T2 (hu) 2020-01-28
US20180161273A1 (en) 2018-06-14
RU2018107407A (ru) 2019-02-25
JP7476161B2 (ja) 2024-04-30
JP2020007367A (ja) 2020-01-16
US10028912B2 (en) 2018-07-24
PT2768484T (pt) 2019-10-28
NO2019041I1 (no) 2019-11-25
EP2768484A4 (en) 2015-04-22
WO2013059133A1 (en) 2013-04-25
JP2014532623A (ja) 2014-12-08
AU2012326370A1 (en) 2014-06-05
KR20190111139A (ko) 2019-10-01
KR20220141906A (ko) 2022-10-20
LUC00135I1 (pt) 2019-10-25
DK2768484T3 (da) 2019-10-07
JP6133308B2 (ja) 2017-05-24
LUC00135I2 (pt) 2021-02-12
JP6592556B2 (ja) 2019-10-16
NL301016I1 (nl) 2019-10-30
AU2012326370B2 (en) 2017-06-01
IL232161A0 (en) 2014-05-28
RU2018107407A3 (pt) 2021-05-04
BR112014009305A2 (pt) 2017-04-11
JP2024045183A (ja) 2024-04-02
RU2648753C2 (ru) 2018-03-28
KR102452305B1 (ko) 2022-10-07
PL2768484T3 (pl) 2019-12-31
US10166184B2 (en) 2019-01-01
KR102024836B1 (ko) 2019-09-24
CN108853031A (zh) 2018-11-23
JP2022033892A (ja) 2022-03-02
HRP20191683T1 (hr) 2019-12-13
US10835492B2 (en) 2020-11-17
JP2017160211A (ja) 2017-09-14
BR112014009305B1 (pt) 2023-01-24
AU2012326370C9 (en) 2023-05-18
KR102113753B1 (ko) 2020-05-21
US20230172855A1 (en) 2023-06-08
NL301016I2 (nl) 2020-04-16
JP6359717B2 (ja) 2018-07-18
US20190070112A1 (en) 2019-03-07
EP2768484B1 (en) 2019-07-24
AU2012326370A2 (en) 2014-06-12
KR20200057104A (ko) 2020-05-25
CA2852777A1 (en) 2013-04-25
ES2750368T3 (es) 2020-03-25

Similar Documents

Publication Publication Date Title
HUS1900047I1 (hu) Liofilizált liposzómák
ZA201307355B (en) Composite elements
ZA201306118B (en) Lyophilized formulations
AP2014007621A0 (en) 2-Thiopyrimidinones
PL2993263T3 (pl) Tkanina o bardzo wysokiej sprężystości
EP2691581A4 (en) joint assembly
GB201111183D0 (en) Peptide
EP2778421A4 (en) COMPRESSOR
GB201115910D0 (en) Peptides
EP2691653A4 (en) COMPRESSOR
EP2759709A4 (en) COMPRESSOR
EP2735741A4 (en) COMPRESSOR
GB201619994D0 (en) Improved fabric
GB2487250B (en) Compressor
HK1187628A1 (zh) 新型肽
GB201106391D0 (en) Novel composite
EP2714717A4 (en) PHOENIXINPEPTIDE
GB201106377D0 (en) Novel composite
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5026P (en) Goldstrike Agapanthus inapertus
GB201115014D0 (en) Peptides
GB201117700D0 (en) Improved fabric
EP2803858A4 (en) COMPRESSOR
GB201114292D0 (en) Fabric
GB201113241D0 (en) Fabric dewrinkler